# US 2020/0368325 A1 · Treatment of short bowel syndrome patients with colon-in-continuity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0368325 A1
- Document ID: US20200368325A1
- Status: Published application
- Kind: A1
- Application number: 16/992,751
- Filed: 2020-08-13
- Published: 2020-11-26
- Earliest claimed: 2004-11-01
- Assignees: Shire-NPS Pharmaceuticals, Inc.
- Applicants: Shire-NPS Pharmaceuticals, Inc.
- Inventors: Elizabeth L. SANGUINETTI; Thomas B. MARRIOTT; Jennifer LOPANSRI; Consuelo M. BLOSCH
- Web page: https://patentgrep.com/patent/US20200368325A1

## CPC

- A61K 38/26: Glucagons
- A61B 5/4222: {Evaluating particular parts, e.g. particular organs}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)

## Abstract

Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.

## Claims

### Claim 1

A method of increasing the number of mitotic figures per 100 crypt epithelial cells in the jejunum of an adult human patient having short bowel syndrome and reduced mitotic figures per 100 crypt epithelial cells in the jejunum as compared to a normal healthy individual, who receives an amount of parenteral nutrition each week, and who presents with colon-in-continuity with remnant small intestine, said method comprising administering [Gly2]hGLP-2 to said patient using a dosing regimen effective to increase the number of mitotic figures per 100 crypt epithelial cells of said patient.

### Claim 2 (depends on 1)

The method as defined in claim 1, wherein the [Gly2]hGLP-2 is administered at a daily dose of from 5 to 500 μg/kg.

### Claim 3 (depends on 2)

The method as defined in claim 2, wherein the [Gly2]hGLP-2 is administered at a daily dose of from 30 to 150 μg/kg.

### Claim 4 (depends on 1)

The method as defined in claim 1, wherein the [Gly2]hGLP-2 is administered by subcutaneous injection.

### Claim 5 (depends on 4)

The method as defined in claim 4, wherein the subcutaneous injection is into the abdomen, thigh, or arm.

### Claim 6 (depends on 1)

The method as defined in claim 1, wherein said regimen comprises administration of the [Gly2]hGLP-2 over a period of at least 21 days.

### Claim 7 (depends on 1)

The method as defined in claim 1, wherein the [Gly2]hGLP-2 is administered at a daily dose of from 30 to 150 μg/kg by subcutaneous injection.
